Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

Company Overview - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules aimed at improving the lives of patients with genetically defined rare diseases [3] - The company has two lead programs in clinical development: losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for sickle cell disease (SCD) and other hemoglobinopathies [3] - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression to address the root causes of gene mis-expression [3] Financial Results Announcement - Fulcrum Therapeutics will release its second quarter 2024 financial results on July 31, 2024, before the U.S. financial markets open [2] - Management will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results and provide updates on recent corporate developments [2]